article thumbnail

Health Canada gives approval to Enhertu for breast cancer treatment

Pharmaceutical Technology

Enhertu has been approved to treat HER2-low breast cancer adult patients who have previously received at least one line of chemotherapy in the metastatic setting or who have seen disease recurrence during or within six months after the adjuvant chemotherapy. Enhertu’s safety profile was consistent with the previous clinical trials.

article thumbnail

FDA approves Regeneron’s Libtayo and chemotherapy combination for NSCLC

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals ’ PD-1 inhibitor Libtayo (cemiplimab-rwlc) and chemotherapy combination as the first-line treatment for advanced non-small cell lung cancer (NSCLC). The regulatory approval is based on results obtained from the international Phase III EMPOWER-Lung 3 trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How pharmacists can counsel patients on a bad reaction to a new medication

The Checkup by Singlecare

Nonimmunologic reactions. Nonimmunologic reactions are reactions that don’t involve the immune system and are not typically considered true allergic reactions. Instead, these non-allergic adverse reactions may be caused by the drug itself or unknown reasons. Most common culprits of reactions.

article thumbnail

FDA grants approval to Gilead Sciences’ breast cancer therapy

Pharmaceutical Technology

The FDA approval is based on the data obtained from a global, multicentre, open-label Phase III TROPiCS-02 study conducted in 543 HR+/HER2- metastatic breast cancer patients who have received prior endocrine therapy, CDK4/6 inhibitor and two to four lines of chemotherapy for metastatic disease. Trodelvy showed 3.2

FDA 105
article thumbnail

US FDA approves Incyte’s merkel cell carcinoma therapy

Pharmaceutical Technology

Zynyz monotherapy showed a 52% objective response rate (ORR) in chemotherapy-naïve patients. Diarrhoea, rash, pyrexia, nausea, musculoskeletal pain, fatigue and pruritus are the most common adverse reactions observed in patients treated with Zynyz. Partial response was seen in 22 patients and complete response in 12 patients.

FDA 98
article thumbnail

Japan’s MHLW approves Daiichi Sankyo’s breast cancer treatment

Pharmaceutical Technology

The treatment is indicated for usage in such patients following previous chemotherapy, comprising trastuzumab and a taxane. Nausea, fatigue, vomiting, reduced neutrophil count, alopecia and anaemia among others were observed to be the most prevalent adverse reactions.

article thumbnail

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies

pharmaphorum

The FDA’s approval covers use of Venclexta (venetoclax) in combination with azacytidine, or decitabine, or low-dose cytarabine (LDAC) for newly diagnosed AML in adults 75 years or older, or who have comorbidities preventing intensive induction chemotherapy. months compared with 4.1 months for those treated with LDAC alone.